Adaptive Biotechnologies (ADPT) Total Non-Current Liabilities (2019 - 2026)

Adaptive Biotechnologies has disclosed Total Non-Current Liabilities across 7 years of filings, most recently posting $281.7 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $281.7 million, down 12.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $281.7 million (down 12.14% YoY), and the FY2025 annual result was $287.7 million, down 14.59% from the prior year.
• Total Non-Current Liabilities came in at $281.7 million for Q1 2026 at Adaptive Biotechnologies, down from $287.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $343.4 million in Q2 2024 to a low of $240.4 million in Q2 2023.
• The 5-year median for Total Non-Current Liabilities is $287.0 million (2025), against an average of $294.0 million.
• Across the five-year window, Total Non-Current Liabilities soared 42.85% in 2024 and fell 14.59% in 2025, its largest moves.
• Adaptive Biotechnologies' Total Non-Current Liabilities stood at $267.2 million in 2022, then dropped by 10.01% to $240.4 million in 2023, then soared by 40.13% to $336.9 million in 2024, then decreased by 14.59% to $287.7 million in 2025, then decreased by 2.1% to $281.7 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $281.7 million (Q1 2026), $287.7 million (Q4 2025), and $286.3 million (Q3 2025), per Business Quant data.